The data presented confirmed the benefits of follitropin delta dosing based on AMH and body weight, regardless ethnicity, resulting in a balanced efficacy and safety outcome with decreased risk of OHSS and reduced gonadotropin use. The gene discussed is AMH; the disease is ovarian hyperstimulation syndrome.